Panelists:
Krystelle Godbout, MD, FRCPC
Quebec Heart and Lung Institute, Quebec City, QC

Richard Leigh, MBChB, MSc, PhD, FCP (SA), FRCPC, FCAHS
University of Calgary, Calgary, AB

Imran Satia, MD, MRCP (UK), PhD
McMaster University; Hamilton, ON

Moderator
Richard Leigh, MBChB, MSc, PhD, FCP (SA), FRCPC, FCAHS
University of Calgary, Calgary, AB

Session Description

Disease modification has emerged as a novel treatment goal in asthma management, and direct targeting of the type 2 cytokines (IL-4, IL-5, IL-13) and proteins (IgE, TSLP) has revealed them to be key factors in the underlying inflammatory processes driving disease. Traditionally, eosinophils have been the key cells implicated in mediating this inflammation, however, the latest research has advanced our understanding beyond the eosinophil to demonstrate how these targets impact airway fibrosis and remodeling. These dynamics are essential to better predict and prevent airway changes in clinical practice and thereby advance our understanding of the next frontier in asthma care.

Learning Objectives

At the end of this presentation, attendees will be able to:

  • Provide an overview of the key cytokines (IL-4, IL-5, and IL-13) in type 2 inflammation and their central role in the pathobiology of asthma
  • Determine how the latest evidence beyond the eosinophil broadens our understanding of type 2 inflammation
  • Explore how the mechanisms of inflammation, airway remodeling in asthma, and the role of targeted inhibition are applicable in clinical practice

CanMEDS Roles: Collaborator, Communicator, Health advocate, Leader, Medical Expert, Scholar

This session is co-developed by the CTS and GSK and is planned to achieve scientific integrity, objectivity and balance.